RW Effectiveness of Lurbinectedin in Extensive Stage SCLC

Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Study ID
NCT05285033
Status
Completed

Conditions

  • Small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Lurbinectedin — DRUG
    Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).

Study Details

LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness and safety of lurbinectedin in real-world conditions.

Key Dates

Start date
Apr 1, 2022
Status verified
Jan 2023
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022

Study Design

Enrollment
312 participants (actual)

Primary Outcome Measure

demographic and clinical characteristics of patients [ Time Frame: 8 months ]

Related Studies